Efficacy of GLP-1 Receptor Agonists and DPP-4 Inhibitors: Meta-Analysis and Systematic Review

Clinical Therapeutics

Volumn 34, Issue 6, 2012, Pages

  Aroda, Vanita R ^a   Henry, Robert R ^b   Han, Jenny ^c   Huang, Wenying ^c   DeYoung, Mary Beth ^c   Darsow, Tamara ^c   Hoogwerf, Byron J ^d  

^a MEDSTAR RESEARCH INSTITUTE   (United States)

^b UNIVERSITY OF CALIFORNIA   (United States)

^c AMYLIN PHARMACEUTICALS INC   (United States)

^d ELI LILLY AND COMPANY   (United States)

Author keywords

Body weight; DPP 4 inhibitors; Fasting plasma glucose; GLP 1; Incretin mimetics; Meta analysis; Systematic review

Indexed keywords

ALBIGLUTIDE; ALOGLIPTIN; ANTIDIABETIC AGENT; DIPEPTIDYL PEPTIDASE IV INHIBITOR; EMPAGLIFLOZIN; EXENDIN 4; GLIBENCLAMIDE; GLICLAZIDE; GLIMEPIRIDE; GLIPIZIDE; GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; GLUCOSE; HEMOGLOBIN A1C; INSULIN; LINAGLIPTIN; LIRAGLUTIDE; LIXISENATIDE; METFORMIN; PIOGLITAZONE; PLACEBO; ROSIGLITAZONE; SAXAGLIPTIN; SITAGLIPTIN; SULFONYLUREA; TASPOGLUTIDE; VILDAGLIPTIN; VOGLIBOSE;

BODY WEIGHT; DIET; DRUG EFFICACY; DRUG MEGADOSE; EVENING DOSAGE; EXERCISE; FOOD AND DRUG ADMINISTRATION; GLUCOSE BLOOD LEVEL; HEMOGLOBIN BLOOD LEVEL; HUMAN; META ANALYSIS; MORNING DOSAGE; PHASE 3 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SYSTEMATIC REVIEW; TREATMENT DURATION; WEIGHT REDUCTION;

EID: 84862152967     PISSN: 01492918     EISSN: 1879114X     Source Type: Journal    
DOI: 10.1016/j.clinthera.2012.04.013     Document Type: Review

References (35)

1. Amori R.E., Lau J., Pittas A.G. Efficacy and safety of incretin therapy in type 2 diabetes: systematic review and meta-analysis. JAMA 2007, 298:194-206.
2. Mentlein R. Dipeptidyl-peptidase IV (CD26)-role in the inactivation of regulatory peptides. Regul Pept 1999, 85:9-24.
3. Drucker D.J., Nauck M.A. The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes. Lancet 2006, 368:1696-1705.
4. Montanya E., Sesti G. A review of efficacy and safety data regarding the use of liraglutide, a once-daily human glucagon-like peptide 1 analogue, in the treatment of type 2 diabetes mellitus. Clin Ther 2009, 31:2472-2488.
5. Bunck M.C., Diamant M., Cornér A., et al. One-year treatment with exenatide improves β-cell function, compared with insulin glargine, in metformin-treated type 2 diabetic patients. Diabetes Care 2009, 32:762-768.
6. Fineman M., Flanagan S., Taylor K., et al. Pharmacokinetics and pharmacodynamics of exenatide extended-release after single and multiple dosing. Clin Pharmacokinet 2011, 50:65-74.
7. Gwaltney S.L. Medicinal chemistry approaches to the inhibition of dipeptidyl peptidase IV. Curr Top Med Chem 2008, 8:1545-1552.
8. Monami M., Marchionni N., Mannucci E. Glucagon-like peptide-1 receptor agonists in type 2 diabetes: a meta-analysis of randomized clinical trials. Eur J Endocrinol 2009, 160:909-917.
9. Ma J., Liu W., Hunter A., Zhang W. Performing meta-analysis with incomplete statistical information in clinical trials. BMC Med Res Methodol 2008, 8:56.
10. Scheen A.J., Charpentier G., Östgren C.J., et al. Efficacy and safety of saxagliptin in combination with metformin compared with sitagliptin in combination with metformin in adult patients with type 2 diabetes mellitus. Diabetes Metab Res Rev 2010, 26:540-549.
11. Bosi E., Dotta F., Jia Y., Goodman M. Vildagliptin plus metformin combination therapy provides superior glycaemic control to individual monotherapy in treatment-naive patients with type 2 diabetes mellitus. Diabetes Obes Metab 2009, 11:506-515.
12. Pratley R.E., Nauck M., Bailey T., et al. Liraglutide versus sitagliptin for patients with type 2 diabetes who did not have adequate glycaemic control with metformin: a 26-week, randomised, parallel-group, open-label trial. Lancet 2010, 375:1447-1456. 1860-LIRA-DPP-4 Study Group.
13. Berg J.K., Shenouda S.K., Heilmann C.R., et al. Effects of exenatide twice daily versus sitagliptin on 24-h glucose, glucoregulatory and hormonal measures: a randomized, double-blind, crossover study. Diabetes Obes Metab 2011, 13:982-989.
14. DeFronzo R.A., Okerson T., Viswanathan P., et al. Effects of exenatide versus sitagliptin on postprandial glucose, insulin and glucagon secretion, gastric emptying, and caloric intake: a randomized, cross-over study. Curr Med Res Opin 2008, 24:2943-2952.
15. Buse J.B., Rosenstock J., Sesti G., et al. Liraglutide once a day versus exenatide twice a day for type 2 diabetes: a 26-week randomised, parallel-group, multinational, open-label trial (LEAD-6). Lancet 2009, 374:39-47. LEAD-6 Study Group.
16. Drucker D.J., Buse J.B., Taylor K., et al. Exenatide once weekly versus twice daily for the treatment of type 2 diabetes: a randomised, open-label, non-inferiority study. Lancet 2008, 372:1240-1250. DURATION-1 Study Group.
17. Buse J.B., Nauck M.A., Forst T., et al. Efficacy and safety of exenatide once weekly versus liraglutide in subjects with type 2 diabetes (DURATION-6): a randomised, open-label study. Diabetologia 2011, 54(Suppl 1):S38.
18. Scott D., Boye K.S., Timlin L., et al. A network meta analysis to compare glycaemic control in patients with type 2 diabetes treated with exenatide once weekly or liraglutide. Value Health 2011, 14:A472-A473.
19. Fakhoury W.K., Lereun C., Wright D. A meta-analysis of placebo-controlled clinical trials assessing the efficacy and safety of incretin-based medications in patients with type 2 diabetes. Pharmacology 2010, 86:44-57.
20. Shyangdan D.S., Royle P.L., Clar C., et al. Glucagon-like peptide analogues for type 2 diabetes mellitus: systematic review and meta-analysis. BMC Endocr Disord 2010, 10:20.
21. McIntosh B., Cameron C., Singh S.R., et al. Second-line therapy in patients with type 2 diabetes inadequately controlled with metformin monotherapy: a systematic review and mixed-treatment comparison meta-analysis. Open Med 2011, 5:e35-e48.
22. Esposito K., Mosca C., Brancario C., et al. GLP-1 receptor agonists and HBA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Curr Med Res Opin 2011, 27:1519-1528.
23. Monami M., Iacomelli I., Marchionni N., Mannucci E. Dipeptydil peptidase-4 inhibitors in type 2 diabetes: a meta-analysis of randomized clinical trials. Nutr Metab Cardiovasc Dis 2010, 20:224-235.
24. Esposito K., Cozzolino D., Bellastella G., et al. Dipeptidyl peptidase-4 inhibitors and HbA1c target of <7% in type 2 diabetes: meta-analysis of randomized controlled trials. Diabetes Obes Metab 2011, 13:594-603.
25. Sherifali D., Nerenberg K., Pullenayegum E., et al. The effect of oral antidiabetic agents on A1C levels: a systematic review and meta-analysis. Diabetes Care 2010, 33:1859-1864.
26. Pinelli N.R., Cha R., Brown M.B., Jaber L.A. Addition of thiazolidinedione or exenatide to oral agents in type 2 diabetes: a meta-analysis. Ann Pharmacother 2008, 42:1541-1551.
27. Pinelli N.R., Hurren K.M. Efficacy and safety of long-acting glucagon-like peptide-1 receptor agonists compared with exenatide twice daily and sitagliptin in type 2 diabetes mellitus: a systematic review and meta-analysis. Ann Pharmacother 2011, 45:850-860.
28. Hanas R., John G. 2010 consensus statement on the worldwide standardization of the hemoglobin A1C measurement. Diabetes Care 2010, 33:1903-1904.
29. Moretto T.J., Milton D.R., Ridge T.D., et al. Efficacy and tolerability of exenatide monotherapy over 24 weeks in antidiabetic drug-naive patients with type 2 diabetes: a randomized, double-blind, placebo-controlled, parallel-group study. Clin Ther 2008, 30:1448-1460.
30. Garber A.J., Foley J.E., Banerji M.A., et al. Effects of vildagliptin on glucose control in patients with type 2 diabetes inadequately controlled with a sulphonylurea. Diabetes Obes Metab 2008, 10:1047-1056.
31. Fleck P., Inzucchi S., Seufert J., et al. Initial therapy with combination alogliptin plus pioglitazone in type 2 diabetes patients inadequately controlled with diet and exercise. Diabetologia 2009, 52(Suppl 1):S294.
32. Rosenstock J., Aguilar-Salinas C., Klein E., et al. Effect of saxagliptin monotherapy in treatment-naive patients with type 2 diabetes. Curr Med Res Opin 2009, 25:2401-2411. CV181-011 Study Investigators.
33. Scott R., Wu M., Sanchez M., Stein P. Efficacy and tolerability of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy over 12 weeks in patients with type 2 diabetes. Int J Clin Pract 2007, 61:171-180.
34. Bergenstal R.M., Wysham C., Macconell L., et al. Efficacy and safety of exenatide once weekly versus sitagliptin or pioglitazone as an adjunct to metformin for treatment of type 2 diabetes (DURATION-2): a randomised trial. Lancet 2010, 376:431-439.
35. Forti A., Garcia E.G., Yu M.B., et al. Efficacy and safety of exenatide administered before the two largest daily meals of Latin American patients with type 2 diabetes. Curr Med Res Opin 2008, 24:2437-2447.